Cited by 321Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

KRAS as a Therapeutic Target

Open access

McCormick, Frank·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-2662PMC PMC4407814

Open this paper in CoChat — free account

Abstract

KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by identifying targets that KRAS cancers depend on for survival. Although drugs that block the well-established downstream pathways, RAF–MAPK and PI3K, are being tested in the clinic, new efforts are under way to exploit previously unrecognized vulnerabilities, such as altered metabolic networks, or novel pathways identified through synthetic lethal screens. Furthermore, new ways of suppressing KRAS gene expression and of harnessing the immune system offer further hope that new ways of treating KRAS are finally coming into view. These issues are discussed in this edition of CCR Focus. Clin Cancer Res; 21(8); 1797–801. ©2015 AACR. See all articles in this CCR Focus section, “Targeting RAS-Driven Cancers.”

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2662

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“In pancreatic cancer, KRAS mutations are detected in the earliest lesions and are retained in all metastases (17).”
Background
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 850
Self-citation
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Self-citation
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744

Show all 41 references

Sorted by citations

Items 101–200 of 321

Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer
Shimomura, I., Yokoi, A., Kohama, I., Kumazaki, M., Tada, Y., Tatsumi, K., Ochiya, T., & Yamamoto, Y. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.002 · Cited by 42
Parameterization of Palmitoylated Cysteine, Farnesylated Cysteine, Geranylgeranylated Cysteine, and Myristoylated Glycine for the Martini Force Field
Atsmon‐Raz, Y., & Tieleman, D. P. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b10175 · Cited by 39
Cutting-Edge Therapies for Lung Cancer
La’ah, A. S., & Chiou, S. (2024) · Cells · doi:10.3390/cells13050436 · Cited by 36
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
Indarte, M., Puentes, R., Maruggi, M., Ihle, N. T., Grandjean, G. V., Scott, M. J., Ahmed, Z., Meuillet, E. J., Zhang, S., Lemos, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2372 · Cited by 37
Prevention and Reversion of Pancreatic Tumorigenesis through a Differentiation-Based Mechanism
Krah, N. M., Narayanan, S. M., Yugawa, D. E., Straley, J. A., Wright, C. V. E., MacDonald, R. J., & Murtaugh, L. C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.012 · Cited by 41
Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer
Boos, S. L., Loevenich, L. P., Vosberg, S., Engleitner, T., Öllinger, R., Kumbrink, J., Rokavec, M., Michl, M., Greif, P. A., Jung, A., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.10.008 · Cited by 39
Synthetic lethality in lung cancer and translation to clinical therapies
Leung, A. W. Y., de Silva, T., Bally, M. B., & Lockwood, W. W. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0546-y · Cited by 35
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
Dietrich, P., Freese, K., Mahli, A., Thasler, W. E., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncotarget · doi:10.18632/oncotarget.23188 · Cited by 36
Small Delivery Vehicles of siRNA for Enhanced Cancer Targeting
Kim, H. J., Yi, Y., Kim, A., & Miyata, K. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00546 · Cited by 33
Sirt1 protects from K‐Ras‐driven lung carcinogenesis
Costa‐Machado, L. F., Martín‐Hernández, R., Sánchez‐Luengo, M. Á., Hess, K., Vales‐Villamarín, C., Barradas, M., Lynch, C. J., de la Nava, D., Díaz‐Ruiz, A., de Cabo, R., et al. (2018) · EMBO Reports · doi:10.15252/embr.201643879 · Cited by 34
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 34
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
Booth, L. A., Roberts, J. L., Poklepovic, A. S., Kirkwood, J. M., Sander, C., Avogadri-Connors, F., Cutler, R. E., Lalani, A. S., & Dent, P. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1394556 · Cited by 33
Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 33
Fabrication of aptamer-guided siRNA loaded lipopolyplexes for gene silencing of notch 1 in MDA-mb-231 triple negative breast cancer cell line
Gharaibeh, L. F., Alshaer, W., Wehaibi, S., Buqain, R. A., Alqudah, D. A., Al-Kadash, A., Al-Azzawi, H., Awidi, A., & Bustanji, Y. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102733 · Cited by 33
Drugging the Undruggable Ras — Immunotherapy to the Rescue?
June, C. H. (2016) · New England Journal of Medicine · doi:10.1056/nejme1612215 · Cited by 33
RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins
Çetin, M. S., Evenson, W. E., Gross, G. G., Jalali‐Yazdi, F., Krieger, D., Arnold, D. B., Takahashi, T. T., & Roberts, R. W. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.008 · Cited by 32
Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery
Taunk, N. K., Oh, J. H., Shukla‐Dave, A., Beal, K. P., Vachha, B. A., Holodny, A. I., & Hatzoglou, V. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox159 · Cited by 32
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
Daley, B. R., Vieira, H. M., Rao, C., Hughes, J. M., Beckley, Z., Huisman, D. H., Chatterjee, D., Sealover, N. E., Cox, K., Askew, J. W., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313137120 · Cited by 30
Phosphorylation of the C-Raf N Region Promotes Raf Dimerization
Takahashi, M., Li, Y., Dillon, T. J., Kariya, Y., & Stork, P. A. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00132-17 · Cited by 27
Characterization of clinically used oral antiseptics as quadruplex-binding ligands
Calabrese, D. R., Zlotkowski, K., Alden, S. L., Hewitt, W. M., Connelly, C. M., Wilson, R. M., Gaikwad, S. M., Chen, L., Guha, R., Thomas, C. J., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky084 · Cited by 30
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Zaman, A., & Bivona, T. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.02 · Cited by 29
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 31
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway
Stevenson, D. A., Schill, L., Schoyer, L., Andresen, B. S., Bakker, A. C., Bayrak‐Toydemir, P., Burkitt‐Wright, E., Chatfield, K. C., Elefteriou, F., Elgersma, Y., et al. (2016) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37723 · Cited by 30
Self-citation
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Zhao, H., Liu, P., Zhang, R., Wu, M. H., Li, D., Zhao, X., Zhang, C., Jiao, B., Chen, B., Chen, Z., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0226-1 · Cited by 30
Inducing stable reversion to achieve cancer control
Powers, S., & Pollack, R. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.12 · Cited by 30
The renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 30
New insights into germ cell tumor genomics
Lafin, J. T., Bagrodia, A., Woldu, S. L., & Amatruda, J. F. (2019) · Andrology · doi:10.1111/andr.12616 · Cited by 28
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State
Yoo, J. H., Brady, S. W., Acosta-Alvarez, L., Rogers, A., Peng, J., Sorensen, L. K., Wolff, R. K., Mleynek, T., Shin, D., Rich, C. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3026 · Cited by 28
CRISPR Diagnosis and Therapeutics with Single Base Pair Precision
Lee, S. H., Park, Y., Jin, Y. B., Kim, S., & Hur, J. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.008 · Cited by 29
Exosomes: Emerging modulators of signal transduction in colorectal cancer from molecular understanding to clinical application
Bahrami, A., Binabaj, M. M., & Ferns, G. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111882 · Cited by 28
A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation
Campbell, K. M., O’Leary, K. A., Rugowski, D. E., Mulligan, W. A., Barnell, E. K., Skidmore, Z. L., Krysiak, K., Griffith, M., Schuler, L. A., & Griffith, O. L. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.098 · Cited by 28
Research Advances in Adenomyosis-Related Signaling Pathways and Promising Targets
Zhang, H., Li, C., Li, W., Xin, W., & Qin, T. (2024) · Biomolecules · doi:10.3390/biom14111402 · Cited by 27
Myristoylated TMEM39AS41, a cell-permeable peptide, causes lung cancer cell death
Park, S., Kim, M., Hong, Y., Lee, H., Tran, Q., Kim, C., Kwon, S. H., Park, J., Park, J., & Kim, S. (2020) · Toxicological Research · doi:10.1007/s43188-020-00038-1 · Cited by 27
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Ward, A., Keeton, A. B., Chen, X., Mattox, T. E., Coley, A. B., Maxuitenko, Y. Y., Buchsbaum, D. J., Randall, T. D., Zhou, G., & Piazza, G. A. (2020) · MedComm · doi:10.1002/mco2.10 · Cited by 28
A CRISPR-Cas9 repressor for epigenetic silencing of KRAS
Liu, J., Sun, M., Cho, K. B., Gao, X., & Guo, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105304 · Cited by 28
Dynamically encoded reactivity of Ras enzymes: opening new frontiers for drug discovery
Pálfy, G., Menyhárd, D. K., & Perczel, A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09917-3 · Cited by 26
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 25
Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis
Wang, X., Li, S., Lin, S., Han, Y., Zhan, T., Huang, Z., Wang, J., Li, Y., Deng, H., Zhang, M., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01085-9 · Cited by 25
Changing the course of pancreatic cancer – Focus on recent translational advances
Javle, M. M., Golan, T., & Maitra, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.004 · Cited by 24
A Quadruple‐Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines
Petruzzella, E., Braude, J. P., Aldrich-Wright, J. R., Gandin, V., & Gibson, D. (2017) · Angewandte Chemie · doi:10.1002/ange.201706739 · Cited by 24
Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy
Jiang-Jiang, Q., Sarkar, S., Voruganti, S., Rajesh, A., Wang, W. T., & Zhang, R. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.30.20160018 · Cited by 24
Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa
Pepper, I., Sciver, R. E. V., & Tang, A. (2017) · BMC Evolutionary Biology · doi:10.1186/s12862-017-1024-x · Cited by 24
MicroRNA-143 as a potential tumor suppressor in cancer: An insight into molecular targets and signaling pathways.
Asghariazar, V., Kadkhodayi, M., Sarailoo, M., Jolfayi, A. G., & Baradaran, B. (2023) · Pathology, Research and Practice · doi:10.1016/j.prp.2023.154792 · Cited by 20
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Bandi, D. S. R., Nagaraju, G. P., Sarvesh, S., Carstens, J. L., Foote, J. B., Graff, E. C., Fang, Y.-H. D., Keeton, A. B., Chen, X., Valiyaveettil, J., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02288-9 · Cited by 28
Grifolin, neogrifolin and confluentin from the terricolous polypore Albatrellus flettii suppress KRAS expression in human colon cancer cells
Yaqoob, A., Li, W. M., Liu, V., Wang, C., Mackedenski, S. J., Tackaberry, L. E., Massicotte, H. B., Egger, K. N., Reimer, K. B., & Lee, C. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231948 · Cited by 23
Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer
Park, H.-J., Park, J.-B., Lee, S.-J., & Song, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081746 · Cited by 23
Arsenite malignantly transforms human prostate epithelial cells in vitro by gene amplification of mutated KRAS
Merrick, B. A., Phadke, D. P., Bostrom, M. A., Shah, R., Wright, G. M., Wang, X., Gordon, O., Pelch, K. E., Auerbach, S. S., Paules, R. S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215504 · Cited by 23
New developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 23
Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells
Kutkowska, J., Strządała, L., & Rapak, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103234 · Cited by 22
Big data and artificial intelligence discover novel drugs targeting proteins without 3D structure and overcome the undruggable targets
He, H., Liu, B., Luo, H., Zhang, T., & Jiang, J. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000323 · Cited by 22
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Sciver, R. E. V., Lee, M., Lee, C. G. L., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis
Tian, C., Li, X., & Ge, C. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00322-2 · Cited by 21
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O. G., Zatarain-Barrón, L., Ordóñez‐Reyes, C., Jaller, E., Rojas, L., Russo, A., et al. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211066064 · Cited by 22
The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv, J., Wang, J., Chang, S., Liu, M., & Pang, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv102 · Cited by 22
Inhibition of RAS: proven and potential vulnerabilities
Zuberi, M., Khan, I., & O’Bryan, J. P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190023 · Cited by 20
Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway
Seo, H., Song, J., Kim, M.-Y., Han, D., Park, H.-J., & Song, M. (2018) · Nutrients · doi:10.3390/nu11010020 · Cited by 19
KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer
Yang, Y., Sang, Z., Ma, J., Zhu, Y., & Wu, S. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2969 · Cited by 19
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
Vaclová, T., Chakraborty, A., Sherwood, J. L., Ross, S. J., Carroll, D. K., Barrett, J. C., Downward, J., & de Bruin, E. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06369-3 · Cited by 20
In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis
Tu, G., Liu, Q., Qiu, Y., Leung, E. L., & Yao, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213845 · Cited by 19
Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer
Ohm, A. M., Tan, A. C., Heasley, L. E., & Reyland, M. E. (2017) · Oncogene · doi:10.1038/onc.2017.27 · Cited by 19
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 19
9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
Poloznikov, A. A., Nikulin, S. V., Болотина, Л. В., Качмазов, А. А., Raigorodskaya, M. P., Kudryavtseva, A. V., Bakhtogarimov, I. R., Rodin, S., Gaisina, I. N., Topchiy, M. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777114 · Cited by 18
Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative Stress
Cinque, G., Ferino, A., Pedersen, E. B., & Xodo, L. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176237 · Cited by 18
Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance
Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 23
Short-term effects of simulated microgravity on morphology and gene expression in human breast cancer cells
Strube, F., Infanger, M., Dietz, C., Romswinkel, A., & Kraus, A. (2019) · Physiology International · doi:10.1556/2060.106.2019.29 · Cited by 17
Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead
Sundar, R., Tan, I. B. H., & Chee, C. E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01977 · Cited by 17
Identifying Key Genes Involved in Axillary Lymph Node Metastasis in Breast Cancer Using Advanced RNA-Seq Analysis: A Methodological Approach with GLMQL and MAS
Rezapour, M., Wesolowski, R., & Gürcan, M. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137306 · Cited by 18
Targeting Mutant KRAS for Anticancer Therapy
Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15
1H, 13C, and 15N chemical shift assignments of a G-quadruplex forming sequence within the KRAS proto-oncogene promoter region
Marquevielle, J., Kumar, M., Mergny, J., & Salgado, G. F. J. (2017) · Biomolecular NMR Assignments · doi:10.1007/s12104-017-9793-0 · Cited by 16
New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics
Esposito, D., Stephen, A. G., Turbyville, T. J., & Holderfield, M. T. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.006 · Cited by 16
Mycochemicals against Cancer Stem Cells
Tacchini, M., Sacchetti, G., Guerrini, A., & Paganetto, G. (2023) · Toxins · doi:10.3390/toxins15060360 · Cited by 15
Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2
Gong, Z., Xue, L., Vlantis, A. C., van Hasselt, C. A., Chan, J., Fang, J., Wang, R., Yang, Y., Li, D., Zeng, X., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02248-4 · Cited by 15
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers
Dai, X., Xia, H., Zhou, S., Tang, Q., & Bi, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.022 · Cited by 15
New (Iso)quinolinyl-pyridine-2,6-dicarboxamide G-Quadruplex Stabilizers. A Structure-Activity Relationship Study
Cadoni, E., Magalhães, P. R., Emídio, R. M., Mendes, E., Vítor, J. M. B., Carvalho, J., Cruz, C., Victor, B. L., & Paulo, A. (2021) · Pharmaceuticals · doi:10.3390/ph14070669 · Cited by 15
The Importance of Mg 2+ ‐Free State in Nucleotide Exchange of Oncogenic K‐Ras Mutants
Pálfy, G., Menyhárd, D. K., Ákontz‐Kiss, H., Vida, I., Batta, G., Tőke, O., & Perczel, A. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202201449 · Cited by 14
Anticancer effect of a pyrrole‐imidazole polyamide‐triphenylphosphonium conjugate selectively targeting a common mitochondrial DNA cancer risk variant in cervical cancer cells
Yao, J., Takenaga, K., Koshikawa, N., Kida, Y., Lin, J. C., Watanabe, T., Maru, Y., Hippo, Y., Yamamoto, S., Zhu, Y., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34319 · Cited by 15
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies
Sealover, N. E., Theard, P. L., Hughes, J. M., Linke, A. J., Daley, B. R., & Kortum, R. L. (2023) · iScience · doi:10.1016/j.isci.2023.108711 · Cited by 14
TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis
Ando, J., Saito, M., Imai, J., Ito, E., Yanagisawa, Y., Honma, R., Saito, K., Tachibana, K., Momma, T., Ohki, S., et al. (2017) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.2017-08 · Cited by 15
Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer
Lee, J. E., Woo, M. G., Jung, K. H., Kang, Y. W., Shin, S., Son, M. K., Fang, Z., YAN, H. H., Park, J. H., Yoon, Y., et al. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.145 · Cited by 15
Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
Alcaraz-Sanabria, A. L., Morafraile, E. C., Fernández-Hinojal, G., Velasco, G., Pérez‐Segura, P., Pandiella, A., Győrffy, B., & Ocaña, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786069 · Cited by 16
Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
Wang, Z., Du, H., Chen, C., Liu, X., & Ke, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.801320 · Cited by 14
Two Distinct Structures of Membrane‐Associated Homodimers of GTP‐ and GDP‐Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement
Lee, K., Fang, Z., Enomoto, M., Gasmi-Seabrook, G. M. C., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie · doi:10.1002/ange.202001758 · Cited by 15
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras
Bahr, J. C., Robey, R. W., Luchenko, V. L., Basseville, A., Chakraborty, A. R., Kozlowski, H., Pauly, G. T., Patel, P., Schneider, J. P., Gottesman, M. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12001 · Cited by 15
Synbindin deficiency inhibits colon carcinogenesis by attenuating Wnt cascade and balancing gut microbiome
Ai, L., Ren, Y., Li, Y., Chen, H., Qian, Y., Lu, S., Xu, A., Ren, L., Zhao, S., Chen, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32074 · Cited by 14
RAS pathway biomarkers for breast cancer prognosis.
van Reesema, L. L. S., Lee, M. P., Zheleva, V. P., Winston, J. S., O'Connor, C. F., Perry, R. R., Hoefer, R. A., & Tang, A. (2016) · PubMed · Cited by 14
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Wang, Y., Lakoma, A., & Zogopoulos, G. (2020) · Genes · doi:10.3390/genes11091098 · Cited by 14
Establishing the mutational effect on the binding susceptibility of AMG510 to KRAS switch II binding pocket: Computational insights
Issahaku, A. R., Aljoundi, A., & Soliman, M. E. S. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100952 · Cited by 13
Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells
Park, J. M., Su, Y., Fan, C.-S., Chen, H., Qiu, Y.-K., Chen, L.-L., Chen, H., Ramasamy, T. S., Chang, J., Huang, S., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01300-4 · Cited by 13
Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1
Posada, I. M. D., Lectez, B. L. P., Siddiqui, F. A., Oetken-Lindholm, C., Sharma, M., & Abankwa, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-09387-8 · Cited by 13
A Ras-LSD1 axis activates PI3K signaling through PIK3IP1 suppression
Lee, K., Kitagawa, M., Liao, P.-J., Virshup, D. M., & Lee, S. (2020) · Oncogenesis · doi:10.1038/s41389-019-0185-4 · Cited by 13
Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study
Liang, F., Kang, Z., Sun, X., Chen, J., Duan, X., He, H., & Cheng, J. (2023) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-023-00498-1 · Cited by 12
The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells
Chen, M., Chen, M., Fu, Y., & Zhang, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154603 · Cited by 12
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives
He, Q., Liu, X., Jiang, L., Liu, P., Xuan, W., Wang, Y., Meng, R., Feng, H., Lv, S., Miao, Q., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2441499 · Cited by 13
Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC
Zhang, H., Nabel, C. S., Li, D., O’Connor, R. Í., Crosby, C. R., Chang, S. M., Yuan, H., Stanley, R., Sahu, S., Levin, D. S., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.014 · Cited by 11
Discovery of novel SOS1 inhibitors using machine learning
Duo, L., Chen, Y., Liu, Q., Ma, Z., Farjudian, A., Ho, W. Y., Low, S. S., Ren, J., Hirst, J. D., Xie, H. Q., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00063c · Cited by 11
Bottlebrush Polymers with Sequence-Controlled Backbones for Enhanced Oligonucleotide Delivery
Wei, Y., Chen, P., Ren, M., Li, D., Lin, J., Sun, T., Wang, Y., Yang, S., Nenopoulos, C., Oetheimer, C., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c13285 · Cited by 13
Proteome-wide Interrogation of Small GTPases Regulated by N 6‑Methyladenosine Modulators
Yang, Y., Yu, K., Li, L., Huang, M., & Wang, Y. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02203 · Cited by 11
Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex
Wang, X., Xie, Q. M., Ji, Y., Yang, J., Shen, J., Peng, F., Zhang, Y., Jiang, F., Kong, X., Ma, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111972 · Cited by 11
K-Ras Activation Induces Differential Sensitivity to Sulfur Amino Acid Limitation and Deprivation and to Oxidative and Anti-Oxidative Stress in Mouse Fibroblasts
Sanctis, G. D., Spinelli, M., Vanoni, M., & Sacco, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163790 · Cited by 10

Authors: McCormick, F.
Affiliations: Frederick National Laboratory for Cancer Research (US)
Corresponding author: McCormick, Frank
ORCID: McCormick, Frank
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-04-14
Volume: 21
Issue: 8
Pages: 1797-1801
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-2662
PMC: PMC4407814
OpenAlex: W2062410054
Cited by: 320
References: 41
Citations by year: 2026: 10 · 2025: 22 · 2024: 18 · 2023: 35 · 2022: 26 · 2021: 32 · 2020: 45 · 2019: 35 · 2018: 31 · 2017: 29 · 2016: 26 · 2015: 10
FWCI: 3.10
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (U01CA168370)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: KRAS, KRAS-targeted therapy, MAPK/ERK pathway, PI3K signaling, synthetic lethality, cancer metabolism, cancer immunotherapy, KRAS oncogenic signaling, drug discovery
MeSH terms: Animals, Antineoplastic Agents, Cell Transformation, Neoplastic, Humans, Immunity, Immunotherapy, Mutation, Neoplasms, Genetic Therapy, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Protein Subunits, RNA Interference, RNA, Small Interfering, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

KRAS as a Therapeutic Target

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks